Literature DB >> 11507188

Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.

C Marusic1, P Rizza, L Lattanzi, C Mancini, M Spada, F Belardelli, E Benvenuto, I Capone.   

Abstract

The high-yield expression of a neutralizing epitope from human immunodeficiency virus type 1 (HIV-1) on the surface of a plant virus and its immunogenicity are presented. The highly conserved ELDKWA epitope from glycoprotein (gp) 41 was expressed as an N-terminal translational fusion with the potato virus X (PVX) coat protein. The resulting chimeric virus particles (CVPs), purified and used to immunize mice intraperitoneally or intranasally, were able to elicit high levels of HIV-1-specific immunoglobulin G (IgG) and IgA antibodies. Furthermore, the human immune response to CVPs was studied with severe combined immunodeficient mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID). hu-PBL-SCID mice immunized with CVP-pulsed autologous dendritic cells were able to mount a specific human primary antibody response against the gp41-derived epitope. Notably, sera from both normal and hu-PBL-SCID mice showed an anti-HIV-1-neutralizing activity. Thus, PVX-based CVPs carrying neutralizing epitopes can offer novel perspectives for the development of effective vaccines against HIV and, more generally, for the design of new vaccination strategies in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507188      PMCID: PMC115088          DOI: 10.1128/jvi.75.18.8434-8439.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Assembly and movement of a plant virus carrying a green fluorescent protein overcoat.

Authors:  S S Cruz; S Chapman; A G Roberts; I M Roberts; D A Prior; K J Oparka
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.

Authors:  M Purtscher; A Trkola; A Grassauer; P M Schulz; A Klima; S Döpper; G Gruber; A Buchacher; T Muster; H Katinger
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

3.  The organization of potato virus X coat proteins in virus particles studied by tritium planigraphy and model building.

Authors:  L A Baratova; N I Grebenshchikov; E N Dobrov; A V Gedrovich; I A Kashirin; A V Shishkov; A V Efimov; L Järvekülg; Y L Radavsky; M Saarma
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

Review 4.  A rational basis for mucosal vaccination against HIV infection.

Authors:  T Lehner; L Bergmeier; Y Wang; L Tao; E Mitchell
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

5.  Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.

Authors:  F R Brennan; T Bellaby; S M Helliwell; T D Jones; S Kamstrup; K Dalsgaard; J I Flock; W D Hamilton
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus.

Authors:  T H Turpen; S J Reinl; Y Charoenvit; S L Hoffman; V Fallarme; L K Grill
Journal:  Biotechnology (N Y)       Date:  1995-01

7.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

Review 8.  Mucosal immunity and tolerance: relevance to vaccine development.

Authors:  C Czerkinsky; F Anjuere; J R McGhee; A George-Chandy; J Holmgren; M P Kieny; K Fujiyashi; J F Mestecky; V Pierrefite-Carle; C Rask; J B Sun
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

9.  Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein.

Authors:  M D Ryan; J Drew
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

10.  Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene.

Authors:  H S Mason; T A Haq; J D Clements; C J Arntzen
Journal:  Vaccine       Date:  1998-08       Impact factor: 3.641

View more
  60 in total

1.  Identification of immunogenic hot spots within plum pox potyvirus capsid protein for efficient antigen presentation.

Authors:  M Rosario Fernández-Fernández; Jorge L Martínez-Torrecuadrada; Fernando Roncal; Elvira Domínguez; Juan Antonio García
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 2.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

3.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

Review 4.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

5.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Authors:  Florence M Brunel; Michael B Zwick; Rosa M F Cardoso; Josh D Nelson; Ian A Wilson; Dennis R Burton; Philip E Dawson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 7.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

8.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

9.  Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system.

Authors:  Marcello Donini; Chiara Lico; Selene Baschieri; Stefania Conti; Walter Magliani; Luciano Polonelli; Eugenio Benvenuto
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

10.  Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.

Authors:  Laurent Verkoczy; M Anthony Moody; T Matt Holl; Hilary Bouton-Verville; Richard M Scearce; Jennifer Hutchinson; S Munir Alam; Garnett Kelsoe; Barton F Haynes
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.